Treatment with rituximab as an opportunity for the prevention of infectious complications
Authors:
Pavel Polák 1,2; Miroslav Penka 1,3,4; Petr Smejkal 1,3; Gabriela Chlupová 1
Authors‘ workplace:
Oddělení klinické hematologie FN Brno
1; Klinika interní, geriatrie, ošetřovatelství a praktického lékařství LF MU a FN Brno, pracoviště Bohunice
2; Katedra laboratorních metod LF MU Brno
3; Interní hematologická a onkologická klinika LF MU a FN Brno, pracoviště Bohunice
4
Published in:
Vnitř Lék 2016; 62(5): 398-405
Category:
Reviews
Overview
Rituximab, a monoclonal antibody against the surface antigen of B-lymphocytes CD20 is beeing used in the treatment of numerous hematological, hematooncological and autoimmune disorders. After administration of rituximab, quick and almost complete depletion of B-lymphocytes with the exception of pre-B-lymphocytes and plasma cells occur. Neutropenia and low serum antibody levels in classes IgA, IgM and IgG may also develop. These changes usually persist for 6–12 months, rarely for several years. In the consequence, patients with the rituximab treatment are more prone to infections – usually of bacterial and viral origin. Concomitantly, rituximab treatment influences negatively postvaccination antibody production and therefore adequate preventive measures are necessary before the beginning of the treatment. The authors offer complex overview of actual literature, emphasize adequate education of patients as well as of healthcare providing staff and discuss the vaccination recommendation against preventable communicable diseases like influenza, pneumococcal diseases, tetanus, diphtheria and pertussis.
Key words:
autoimmune disease – immunosupression – infectious complications – prevention – rituximab – vaccination
Sources
1. Makatsori M, Kiani-Alikhan S, Manson AL et al. Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes. QJM 2014; 107(10): 821–828.
2. Adam Z, Pejchalová A, Chlupová G et al. Nemoc chladových aglutininů nereagující na léčbu glukokortikoidy a na léčbu rituximabem. Jaký postup zvolit pro III. linii léčby? Popis případu a přehled literatury. Vnitř Lék 2013; 59(9): 828–840.
3. Červinek L, Černá O, Čaniga M et al. Efficacy of rituximab in primary immune thrombocytopenia: an analysis of adult pretreated patients from everyday hematological practice. Int J Hematol 2012; 96(5): 594–599.
4. Hrodek O. A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Transfuze a hematologie dnes 2011; 17(4): 187.
5. Zappasodi R, de Braud F, Di Nicola M. Lymphoma immunotherapy: current status. Front Immunol 2015; 6: 448.
6. Hutchinson AL, Tan YL, Kidson-Gerber G. A case of an acquired factor VIII inhibitor complicated by multiple treatment-related opportunistic infections and review of the literature. Case Rep Hematol 2013; 2013: 703027. Dostupné z DOI: <http://dx.doi.org/10.1155/2013/703027>.
7. Worch J, Makarova O, Burkhardt B. Immunreconstitution and infectious complications after rituximab treatment in children and adolescents: what do we know and what can we learn from adults? Cancers (Basel) 2015; 7(1): 305–328.
8. Souhrn údajů o přípravku. Dostupné z WWW: <http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/000165/WC500025821.pdf>.
9. Hirai Y, Ainoda Y, Shoji T et al. Disseminated cryptococcosis in a non-Hodgkin’s lymphoma patient with late-onset neutropenia following rituximab-CHOP chemotherapy: a case report and literature review. Mycopathologia 2011; 172(3): 227–232.
10. Salmon JH, Cacoub P, Combe B et al. Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the AutoImmunity and Rituximab registry. RMD Open 2015; 1(1): e000034. Dostupné z DOI: <http://dx.doi.org/10.1136/rmdopen-2014–000034>.
11. Palacios T, Bartelt L, Scheld W et al. Fatal Coxsackie meningoencephalitis in a patient with B-cell lymphopenia and hypogammaglobulinemia following rituximab therapy. Ann Allergy Asthma Immunol 2015; 115(2): 148–150.
12. Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13(2): 106–111.
13. van Vollenhoven RF, Fleischmann RM, Furst DE et al. Longterm safety of rituximab: final report of the rheumatoid arthritis global clinical trial program over 11 years. J Rheumatol 2015; 42(10): 1761–1766.
14. Oren S, Mandelboim M, Braun-Moscovici Y et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis 2008; 67(7): 937–941.
15. Lanini S, Molloy AC, Prentice AG et al. Infections in patients taking rituximab for hematologic malignancies: two-year cohort study. BMC Infect Dis 2013; 13: 317. Dostupné z DOI: <http://dx.doi.org/10.1186/1471–2334–13–317>.
16. Chen DR, Cohen PL. Living life without B cells: is repeated B-cell depletion a safe and effective long-term treatment plan for rheumatoid arthritis? Int J Clin Rheumatol 2012; 7(2): 159–166.
17. Heusele M, Clerson P, Guery B et al. Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 2014; 33(6): 799–805.
18. Morjaria S, Arguello E, Taur Y et al. West Nile virus central nervous system infection in patients treated with rituximab: implications for diagnosis and prognosis, with a review of literature. Open Forum Infect Dis 2015; 2(4): ofv136. Dostupné z DOI: <http://dx.doi.org/10.1093/ofid/ofv136>.
19. Morgan C, Thomson SJ, Legg J et al. A case of fulminant hepatitis due to echovirus 9 in a patient on maintenance rituximab therapy for follicular lymphoma. Case Rep Hematol 2015; 2015: 454890. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/454890>.
20. Tsai MJ, Chou CW, Lin FC et al. Pneumocystis jiroveci pneumonia in patients with systemic lupus erythematosus after rituximab therapy. Lupus 2012; 21(8): 914–918.
21. Holik H, Coha B, Šiško M et al. Leuconostoc sp. meningitis in a patient treated with rituximab for mantle cell lymphoma. Turk J Haematol 2015; 32(3): 271–274.
22. Hilal T. Fatal cytomegalovirus disease after combination therapy with corticosteroids and rituximab for granulomatosis with polyangiitis. Case Rep Rheumatol 2015; 2015: 538137. Dostupné z DOI: <http://dx.doi.org/10.1155/2015/538137>.
23. Okamoto A, Abe A, Okamoto M et al. Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy. Int J Hematol 2012; 96(4): 516–520.
24. Yang SH, Lin LW, Fang YJ et al. Parvovirus B19 infection-related acute hepatitis after rituximab-containing regimen for treatment of diffuse large B-cell lymphoma. Ann Hematol 2012; 91(2): 291–294.
25. Hsiao LT, Chiou TJ, Gau JP et al. Risk of reverse seroconversion of hepatitis B virus surface antigen in rituximab-treated non-hodgkin lymphoma patients: a large cohort retrospective study. Medicine (Baltimore) 2015; 94(32): e1321. Dostupné z DOI: <http://dx.doi.org/10.1097/MD.0000000000001321>.
26. Tonziello G, Pisaturo M, Sica A et al. Transient reactivation of occult hepatitis B virus infection despite lamivudine prophylaxis in a patient treated for non-Hodgkin lymphoma. Infection 2013; 41(1): 225–229.
27. Moulis G, Lapeyre-Mestre M, Mahévas M et al. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol 2015; 90(4): 301–305.
28. Eisenberg RA, Jawad AF, Boyer J et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 2013; 33(2): 388–396.
29. Bühler S, Eperon G, Ribi C et al. Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. Swiss Med Wkly 2015; 145: w14159. Dostupné z DOI: <http://dx.doi.org/10.4414/smw.2015.14159>.
30. Westra J, van Assen S, Wilting KR et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol 2014; 178(1): 40–47.
31. Hua Ch, Barnetche T, Combe B et al. Effect of methotrexate, anti–tumor necrosis factor-α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care & Research 2014; 66(7): 1016–1026.
32. Ide Y, Imamura Y, Ohfuji S et al. Immunogenicity of a monovalent influenza A(H1N1)pdm09 vaccine in patients with hematological malignancies. Hum Vaccin Immunother 2014; 10(8): 2387–2394.
33. Kozáková J, Šebestová H, Křížová P. Invazivní pneumokokové onemocnění v České republice v roce 2014. CEM- SZÚ Praha. Zprávy Centra epidemiologie a mikrobiologie 2015; 24(3): 96–101.
34. Polák P, Kosina P, Blechová Z et al. Doporučený postup péče o pacienty s porušenou či zaniklou funkcí sleziny (hyposplenismem/asplenií). Mezioborové doporučení Společnosti infekčního lékařství a České vakcinologické společnosti ČLS JEP. Dostupné z WWW: <http://www.vakcinace.eu/doporuceni-a-stanoviska>.
35. Polák P, Freibergerová M, Husa P et al. Upozornění na nebezpečí invazivních infekcí u splenektomovaných pacientů. Zkušenosti z FN Brno, 2011. Vnitř Lék 2012; 58(9): 665–667.
36. Stanovisko České revmatologické společnosti k očkování dospělých pacientů s autoimunitním revmatickým onemocněním k prevenci onemocnění způsobených Streptococcus pneumoniae (pneumokokem). Dostupné z WWW: <http://www.revmatologicka-spolecnost.cz/doporucene-postupy-crs>.
37. Vakcinace u dospělých pacientů se solidními nádory a profylaxe infekcí u nemocných po splenektomii. Dostupné z WWW: <http://www.linkos.cz/informace-pro-praxi/modra-kniha/38-vakcinace-u-dospelych-pacientu-se-solidnimi-nadory-a-profylaxe-infekci-u-nemocnych-po-splenektomii/>.
38. Small TN, Zelenetz AD, Noy A et al. Pertussis immunity and response to tetanus-reduced diphtheria-reduced pertussis vaccine (Tdap) after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 2009; 15(12): 1538–1542.
39. Puissant-Lubrano B, Rostaing L, Kamar N et al. Impact of rituximab therapy on response to tetanus toxoid vaccination in kidney-transplant patients. Exp Clin Transplant 2010; 8(1): 19–28.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2016 Issue 5
Most read in this issue
- Hypercalcemia, symptoms, differential diagnostics and treatment, or importance of calcium investigation
- Diagnostics of cystic fibrosis in adults
- Can fish oil improve wound healing in surgery?
- Hepatic transit times and liver elasticity compared with meld in predicting a 1 year adverse clinical outcome of a clinically diagnosed cirrhosis